Abnormal pain processing is an important pathophysiological feature of fibromyalgia, and nonrestorative sleep is a common clinical and diagnostic feature
Polysomnography has demonstrated that patients with fibromyalgia have reduced slow-wave sleep and α-intrusion (α-waves during non-REM [rapid eye movement]), although these sleep disturbances are not unique to fibromyalgia
In healthy individuals. sleep deprivation can induce fibromyalgia-like symptoms and is associated with impairment in descending pain modulation
Population studies implicate poor-quality sleep as a risk factor for the development of widespread pain, and sleep disturbances can cause depression
Sleep dysfunction might have bidirectional roles in the pathophysiology of fibromyalgia
Fibromyalgia is a common cause of chronic widespread pain, characterized by reduced pressure pain thresholds with hyperalgesia and allodynia. In addition to pain, common symptoms include nonrestorative sleep, fatigue, cognitive dysfunction, stiffness and mood disturbances. The latest research indicates that the dominant pathophysiology in fibromyalgia is abnormal pain processing and central sensitization. Neuroimaging studies have shown that patients with fibromyalgia have similar neural activation to healthy age-matched and gender-matched individuals; however, they have a lower pressure-pain threshold. Polysomnography data has demonstrated that these patients have reduced short-wave sleep and abnormal α-rhythms, suggestive of wakefulness during non-REM (rapid eye movement) sleep. Sleep deprivation in healthy individuals can cause symptoms of fibromyalgia, including myalgia, tenderness and fatigue, suggesting that sleep dysfunction might be not only a consequence of pain, but also pathogenic. Epidemiological studies indicate that poor sleep quality is a risk factor for the development of chronic widespread pain among an otherwise healthy population. Mechanistically, sleep deprivation impairs descending pain-inhibition pathways that are important in controlling and coping with pain. Clinical trials of pharmacological and nonpharmacological therapies have shown that improving sleep quality can reduce pain and fatigue, further supporting the hypothesis that sleep dysfunction is a pathogenic stimulus of fibromyalgia.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wolfe, F. Fibromyalgia wars. J. Rheumatol. 36, 671–678 (2009).
Hadler, N. M. “Fibromyalgia” and the medicalization of misery. J. Rheumatol. 30, 1668–1670 (2003).
Queiroz, L. P. Worldwide epidemiology of fibromyalgia. Curr. Pain Headache Rep. 17, 356 (2013).
Wolfe, F., Ross, K., Anderson, J., Russell, I. J. & Hebert, L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 38, 19–28 (1995).
Boonen, A. et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann. Rheum. Dis. 64, 396–402 (2005).
Centers for Disease Control and Prevention. Fibromyalgia [online], (2015).
Hughes, G., Martinez, C., Myon, E., Taïeb, C. & Wessely, S. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum. 54, 177–183 (2006).
Department of Health UK. Annual report of the Chief Medical Officer on the state of public health—Pain: breaking through the barrier [online], (2008).
Choy, E. et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv. Res. 10, 102 (2010).
Wolfe, F., Hawley, D. J. & Wilson, K. The prevalence and meaning of fatigue in rheumatic disease. J. Rheumatol. 23, 1407–1417 (1996).
Nicassio, P. M., Moxham, E. G., Schuman, C. E. & Gevirtz, R. N. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain 100, 271–279 (2002).
Kleinman, L. et al. Assessment of sleep in patients with fibromyalgia: qualitative development of the fibromyalgia sleep diary. Health Qual. Life Outcomes. 12, 111 (2014).
Alciati, A., Sgiarovello, P., Atzeni, F. & Sarzi-Puttini, P. Psychiatric problems in fibromyalgia: clinical and neurobiological links between mood disorders and fibromyalgia. Reumatismo. 64, 268–274 (2012).
Clauw, D. J. Fibromyalgia: a clinical review. JAMA 311, 1547–1555 (2014).
Benedetti, M. et al. Plasma corticosterone levels in mouse models of pain. Eur. J. Pain 16, 803–815 (2012).
Salomons, T. V., Nusslock, R., Detloff, A., Johnstone, T. & Davidson, R. J. Neural emotion regulation circuitry underlying anxiolytic effects of perceived control over pain. J. Cogn. Neurosci. 27, 222–233 (2015).
Abeles, A. M., Pillinger, M. H., Solitar, B. M. & Abeles, M. Narrative review: the pathophysiology of fibromyalgia. Ann. Intern. Med. 146, 726–734 (2007).
Vierck, C. J. Jr. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain 124, 242–263 (2006).
Yunus, M. B. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin. Arthritis Rheum. 36, 339–356 (2007).
Gracely, R. H., Grant, M. A. & Giesecke, T. Evoked pain measures in fibromyalgia. Best Pract. Res. Clin. Rheumatol. 17, 593–609 (2003).
Staud, R. & Spaeth, M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr. 13 (Suppl. 5), 12–17 (2008).
Granot, M. et al. Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia. Clin. Neurophysiol. 112, 1881–1887 (2001).
Lorenz, J., Grasedyck, K. & Bromm, B. Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia. Electroencephalogr. Clin. Neurophysiol. 100, 165–168 (1996).
Gracely, R. H., Petzke, F., Wolf, J. M. & Clauw, D. J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 46, 1333–1343 (2002).
Woolf, C. J. Central sensitization: implications for the diagnosis and treatment of pain. Pain 152 (Suppl. 3), S2–S15 (2011).
Besson, J. M. The neurobiology of pain. Lancet 353, 1610–1615 (1999).
Arendt-Nielsen, L. & Graven-Nielsen, T. Translational musculoskeletal pain research. Best Pract. Res. Clin. Rheumatol. 25, 209–226 (2011).
Traub, R. J. Spinal modulation of the induction of central sensitization. Brain Res. 778, 34–42 (1997).
Todd, A. J. & Koerber, H. R. in Wall and Melzack's Textbook of Pain 5th edn Ch. 4 (eds McMahon, S. B. & Koltzenburg, M.) 73–90 (Elsevier, 2006).
Costigan, M., Scholz, J. & Woolf, C. J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1–32 (2009).
Vaerøy, H., Helle, R., Førre, O., Kåss, E. & Terenius, L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32, 21–26 (1988).
Russell, I. J. et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 37, 1593–1601 (1994).
Larson, A. A., Giovengo, S. L., Russell, I. J. & Michalek, J. E. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 87, 201–211 (2000).
Giovengo, S. L., Russell, I. J. & Larson, A. A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J. Rheumatol. 26, 1564–1569 (1999).
Harris, R. E. et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 60, 3146–3152 (2009).
Bushnell, M. C. & Apkarian, A. V. in Wall and Melzack's Textbook of Pain 5th edn Ch. 6 (eds McMahon, S. B. & Koltzenburg, M.) 107–124 (Elsevier, 2006).
Bradley, L. A. et al. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J. Musculoskel. Pain 7, 285–292 (1999).
Mountz, J. M. et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 38, 926–938 (1995).
Kuchinad, A. et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J. Neurosci. 27, 4004–4007 (2007).
Luerding, R., Weigand, T., Bogdahn, U. & Schmidt-Wilcke, T. Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: structural correlates of pain-cognition interaction. Brain 131, 3222–3231 (2008).
Lutz, J. et al. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion–tensor and volumetric imaging study. Arthritis Rheum. 58, 3960–3969 (2008).
Sundgren, P. C. et al. Diffusion-weighted and diffusion tensor imaging in fibromyalgia patients: a prospective study of whole brain diffusivity, apparent diffusion coefficient, and fraction anisotropy in different regions of the brain and correlation with symptom severity. Acad. Radiol. 14, 839–846 (2007).
Cook, D. B. et al. Functional imaging of pain in patients with primary fibromyalgia. J. Rheumatol. 31, 364–378 (2004).
Kwiatek, R. et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 43, 2823–2833 (2000).
Fields, H. L., Basbaum, A. I. & Heinricher, M. M. in Wall and Melzack's Textbook of Pain 5th edn Ch. 7 (eds McMahon, S. B. & Koltzenburg, M.) 125–142 (Elsevier, 2006).
Pertovaara, A. Noradrenergic pain modulation. Prog. Neurobiol. 80, 53–83 (2006).
Russell, I. J., Vaeroy, H., Javors, M. & Nyberg, F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 35, 550–556 (1992).
Jensen, K. B. et al. Evidence of dysfunctional pain inhibition in fibromyalgia reflected in rACC during provoked pain. Pain 144, 95–100 (2009).
Petrovic, P., Kalso, E., Petersson, K. M. & Ingvar, M. Placebo and opioid analgesia—imaging a shared neuronal network. Science 295, 1737–1740 (2002).
Harris, R. E. et al. Decreased central μ-opioid receptor availability in fibromyalgia. J. Neurosci. 27, 10000–10006 (2007).
Sörensen, J., Bengtsson, A., Bäckman, E., Henriksson, K. & Bengtsson, M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand. J. Rheumatol. 24, 360–365 (1995).
Villanueva, L. & Le Bars, D. The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Biol. Res. 28, 113–125 (1995).
Le Bars, D., Dickenson, A. H. & Besson, J. M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 6, 283–304 (1979).
Lautenbacher, S. & Rollman, G. B. Possible deficiencies of pain modulation in fibromyalgia. Clin. J. Pain 13, 189–196 (1997).
Kosek, E. & Hansson, P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 70, 41–51 (1997).
Julien, N., Goffaux, P., Arsenault, P. & Marchand, S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114, 295–302 (2005).
Staud, R., Robinson, M. E., Vierck, C. J. Jr & Price, D. D. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 101, 167–174 (2003).
Le Bars, D., Gozariu, M. & Cadden, S. W. Animal models of nociception. Pharmacol. Rev. 53, 597–652 (2001).
Vera-Portocarrero, L. P. et al. Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience 140, 1311–1320 (2006).
Porreca, F., Ossipov, M. H. & Gebhart, G. F. Chronic pain and medullary descending facilitation. Trends Neurosci. 25, 319–325 (2002).
Bigatti, S. M., Hernandez, A. M., Cronan, T. A. & Rand, K. L. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 59, 961–967 (2008).
Russell, I. J. & Bieber, C. S. in Wall and Melzack's Textbook of Pain 5th edn Ch. 44 (eds McMahon, S. B. & Koltzenburg, M.) 669–682 (Elsevier, 2006).
Moldofsky, H. The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine 75, 397–402 (2008).
Yunus, M. B., Ahles, T. A., Aldag, J. C. & Masi, A. T. Relationship of clinical features with psychological status in primary fibromyalgia. Arthritis Rheum. 34, 15–21 (1991).
Hauri, P. & Hawkins, D. R. Alpha-delta sleep. Electroencephalogr. Clin. Neurophysiol. 34, 233–237 (1973).
Hamilton, N. A. et al. Fibromyalgia: the role of sleep in affect and in negative event reactivity and recovery. Health Psychol. 27, 490–497 (2008).
Lentz, M. J., Landis, C. A., Rothermel, J. & Shaver, J. L. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J. Rheumatol. 26, 1586–1592 (1999).
Scheuler, W., Stinshoff, D. & Kubicki, S. The alpha-sleep pattern. Differentiation from other sleep patterns and effect of hypnotics. Neuropsychobiology 10, 183–189 (1983).
Anch, A. M., Lue, F. A., MacLean, A. W. & Moldofsky, H. Sleep physiology and psychological aspects of the fibrositis (fibromyalgia) syndrome. Can. J. Psychol. 45, 179–184 (1991).
Sergi, M. et al. Periodic breathing during sleep in patients affected by fibromyalgia syndrome. Eur. Respir. J. 14, 203–208 (1999).
Tononi, G. Slow wave homeostasis and synaptic plasticity. J. Clin. Sleep Med. 5 (Suppl. 2), S16–S19 (2009).
Dijk, D. J. Regulation and functional correlates of slow wave sleep. J. Clin. Sleep Med. 5 (Suppl. 2), S6–S15 (2009).
Roizenblatt, S., Moldofsky, H., Benedito-Silva, A. A. & Tufik, S. Alpha sleep characteristics in fibromyalgia. Arthritis Rheum. 44, 222–230 (2001).
Cantero, J. L., Atienza, M. & Salas, R. M. Human alpha oscillations in wakefulness, drowsiness period, and REM sleep: different electroencephalographic phenomena within the alpha band. Neurophysiol. Clin. 32, 54–71 (2002).
Van Cauter, E. et al. Reciprocal interactions between the GH axis and sleep. Growth Horm. IGF Res. 14 (Suppl. A), S10–S17 (2004).
Drewes, A. M. et al. Sleep intensity in fibromyalgia: focus on the microstructure of the sleep process. Br. J. Rheumatol. 34, 629–635 (1995).
Horne, J. A. & Shackell, B. S. Alpha-like EEG activity in non-REM sleep and the fibromyalgia (fibrositis) syndrome. Electroencephalogr. Clin. Neurophysiol. 79, 271–276 (1991).
Branco, J., Atalaia, A. & Paiva, T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J. Rheumatol. 21, 1113–1117 (1994).
Landis, C. A., Lentz, M. J., Rothermel, J., Buchwald, D. & Shaver, J. L. Decreased sleep spindles and spindle activity in midlife women with fibromyalgia and pain. Sleep 27, 741–750 (2004).
Burns, J. W., Crofford, L. J. & Chervin, R. D. Sleep stage dynamics in fibromyalgia patients and controls. Sleep Med. 9, 689–696 (2008).
Chervin, R. D. et al. Objective measures of disordered sleep in fibromyalgia. J. Rheumatol. 36, 2009–2016 (2009).
Larsen, L. H., Moe, K. E., Vitiello, M. V. & Prinz, P. N. A note on the night-to-night stability of stages 3 + 4 sleep in healthy older adults: a comparison of visual and spectral evaluations of stages 3 + 4 sleep. Sleep 18, 7–10 (1995).
Rizzi, M. et al. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J. Rheumatol. 31, 1193–1199 (2004).
Van Cauter, E., Spiegel, K., Tasali, E. & Leproult, R. Metabolic consequences of sleep and sleep loss. Sleep Med. 9 (Suppl. 1), S23–S28 (2008).
Moldofsky, H. & Scarisbrick, P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom. Med. 38, 35–44 (1976).
Smith, M. T., Edwards, R. R., McCann, U. D. & Haythornthwaite, J. A. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep 30, 494–505 (2007).
Onen, S. H., Alloui, A., Gross, A., Eschallier, A. & Dubray, C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J. Sleep Res. 10, 35–42 (2001).
Roehrs, T., Hyde, M., Blaisdell, B., Greenwald, M. & Roth, T. Sleep loss and REM sleep loss are hyperalgesic. Sleep 29, 145–151 (2006).
Kundermann, B., Spernal, J., Huber, M. T., Krieg, J. C. & Lautenbacher, S. Sleep deprivation affects thermal pain thresholds but not somatosensory thresholds in healthy volunteers. Psychosom. Med. 66, 932–937 (2004).
Mork, P. J. & Nilsen, T. I. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis Rheum. 64, 281–284 (2012).
Wolfe, F. Sleep problems and risk of fibromyalgia—untenable conclusions: comment on the article by Mork et al. Arthritis Rheum. 64, 1692–1693 (2012).
McBeth, J., Lacey, R. J. & Wilkie, R. Predictors of new-onset widespread pain in older adults: results from a population-based prospective cohort study in the UK. Arthritis Rheumatol. 66, 757–767 (2014).
Ablin, J. N. et al. Effects of sleep restriction and exercise deprivation on somatic symptoms and mood in healthy adults. Clin. Exp. Rheumatol. 31 (Suppl. 79), S53–S59 (2013).
Paul-Savoie, E. et al. Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol. J. 6, 296–302 (2012).
Luca, A., Luca, M. & Calandra, C. Sleep disorders and depression: brief review of the literature, case report, and nonpharmacologic interventions for depression. Clin. Interv. Aging 8, 1033–1039 (2013).
Sivertsen, B., Harvey, A. G., Pallesen, S. & Hysing, M. Mental health problems in adolescents with delayed sleep phase: results from a large population-based study in Norway. J. Sleep Res. 24, 11–18 (2014).
Alvaro, P. K., Roberts, R. M. & Harris, J. K. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. Sleep 36, 1059–1068 (2013).
Toussaint, L. L., Vincent, A., McAllister, S. J., Oh, T. H. & Hassett, A. L. A comparison of fibromyalgia symptoms in patients with healthy versus depressive, low and reactive affect balance styles. Scand. J. Pain 5, 161–166 (2014).
Russell, I. J., Perkins, A. T., Michalek, J. E. & Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 60, 299–309 (2009).
Spaeth, M. et al. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann. Rheum. Dis. 71, 935–942 (2012).
Ibrahim, F., Lai, C. & Choy, E. Use of path analysis to evaluate the effects of sodium oxybate on pain reduction in patients with fibromyalgia [abstract 819]. Arthritis Rheum. 61 (Suppl. 10), 819 (2010).
Martínez, M. P. et al. Cognitive-behavioral therapy for insomnia and sleep hygiene in fibromyalgia: a randomized controlled trial. J. Behav. Med. 37, 683–697 (2014).
Fields, H. State-dependent opioid control of pain. Nat. Rev. Neurosci. 5, 565–575 (2004).
The author has served as a member of advisory boards, as a consultant and at speaker's bureaus for Eli Lilly, Jazz Pharmaceuticals, Pierre Fabre Medicament, Pfizer and UCB.
About this article
Cite this article
Choy, E. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol 11, 513–520 (2015). https://doi.org/10.1038/nrrheum.2015.56
Advances in Rheumatology (2021)
Advances in Rheumatology (2021)
Sleep and Breathing (2021)
Nature Reviews Rheumatology (2020)
Sleep and Breathing (2020)